Payment overview · 2025
General Payments
$635.32
29 reported records · 9 companies
Healthcare provider profile · identity verified
Ray Thomas Douglas, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MILTON, PA · NPI 1184643488
Verified facts
What the public records show
CMS Open Payments records show Ray Thomas Douglas, M.D. received $635.32 in general payments during 2025 across 29 reported records.
AstraZeneca Pharmaceuticals LP accounted for 27.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Prolia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $173.77 | 27.4% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $160.35 | 25.2% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $159.37 | 25.1% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $49.03 | 7.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.04 | 3.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.05 | 3.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.50 | 2.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $15.27 | 2.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.94 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $635.32 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $159.37 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $125.65 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $91.54 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $71.11 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $68.81 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $65.34 | 4 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $49.03 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $37.32 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.04 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $15.27 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $13.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 118 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 72 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
118 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
72 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
126 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 503 | 140 |
| Metoprolol Succinate | Metoprolol Succinate | 286 | 93 |
| Lisinopril | Lisinopril | 270 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 265 | 66 |
| Omeprazole | Omeprazole | 221 | 68 |
| Levothyroxine Sodium | Levothyroxine Sodium | 178 | 42 |
| Losartan Potassium | Losartan Potassium | 161 | 50 |
| Metformin Hcl | Metformin Hcl | 146 | 37 |
| Simvastatin | Simvastatin | 144 | 36 |
| Eliquis | Apixaban | 126 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 126 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 124 | 41 |
| Jardiance | Empagliflozin | 118 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 118 | 33 |
| Gabapentin | Gabapentin | 111 | 22 |
| Sertraline Hcl | Sertraline Hcl | 107 | 24 |
| Furosemide | Furosemide | 104 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 103 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 97 | 45 |
| Lorazepam | Lorazepam | 97 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 92 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 91 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 85 | 16 |
| Carvedilol | Carvedilol | 79 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 78 | 19 |
| Famotidine | Famotidine | 77 | 19 |
| Ezetimibe | Ezetimibe | 75 | 24 |
| Ozempic | Semaglutide | 72 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 70 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 17 |
| Potassium Chloride | Potassium Chloride | 62 | 17 |
| Prednisone | Prednisone | 62 | 36 |
| Mirtazapine | Mirtazapine | 60 | 14 |
| Tramadol Hcl | Tramadol Hcl | 58 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | 12 |
| Finasteride | Finasteride | 52 | 15 |
| Alprazolam | Alprazolam | 45 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 20 |
| Atenolol | Atenolol | 40 | 13 |
| Spironolactone | Spironolactone | 40 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 39 | suppressed |
| Torsemide | Torsemide | 39 | suppressed |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 38 | suppressed |
| Baclofen | Baclofen | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 23 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 34 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Amoxicillin | Amoxicillin | 33 | 24 |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Allopurinol | Allopurinol | 32 | 11 |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 31 | 11 |
| Nitroglycerin | Nitroglycerin | 30 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 19 |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 11 |
| Sucralfate | Sucralfate | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Sodium Fluoride 5000 Plus | Fluoride (Sodium) | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 16 | 14 |
| Digoxin | Digoxin | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Prolia | Denosumab | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Lamotrigine Er | Lamotrigine | 12 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $635.32 · 29 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, CAPVAXIVE, COMIRNATY, Dexcom G6 Transmitter, FARXIGA, GARDASIL 9, JARDIANCE, Korlym, MOUNJARO, Ozempic, PREVNAR 20, QULIPTA, TEPEZZA, UBRELVY, VAXELIS | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error